Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
Jan 30, 2026

First published by Lexology. Authors: Safir Anand and Omesh Puri In today’s innovation‑driven economy, design rights have become a core element of

Proposed Reforms to India’s Design Protection Framework
News & Updates, Thought Leadership
Jan 17, 2026

‘First published on Asia IP’ By: Pravin Anand, Madhu Rewari and Ansh Maggo With the increasing commercialization of intellectual property in India,

Arbitrability of intellectual property disputes in India
News & Updates, Thought Leadership
Jan 15, 2026

First published by Lexology. Authors: Safir Anand, Mudit Kaushik and Sehr Anand The handling of price sensitive corporate information has become increasingly

The Regulatory Cost of Informal Digital Disclosures
News & Updates
Jan 02, 2026

First published by Lexology. Authors: Pravin Anand, Saif Khan, Shobhit Agarwal and Prajjwal Kushwaha A. Background B. Legal Issues Addressed C. Directions

Landmark Ruling On Domain Name Fraud and Systematic Reforms in Digital Commerce